{"id":"NCT03738397","sponsor":"AbbVie","briefTitle":"A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis","officialTitle":"A Phase 3b Multicenter, Randomized, Double-Blind, Double-Dummy, Active Controlled Study Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-02-21","primaryCompletion":"2020-08-27","completion":"2020-12-09","firstPosted":"2018-11-13","resultsPosted":"2022-02-02","lastUpdate":"2024-03-15"},"enrollment":673,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Atopic Dermatitis"],"interventions":[{"type":"BIOLOGICAL","name":"Upadacitinib","otherNames":["ABT-494","RINVOQ®"]},{"type":"BIOLOGICAL","name":"Dupilumab","otherNames":["Dupixent®"]},{"type":"DRUG","name":"Placebo to dupilumab","otherNames":[]},{"type":"DRUG","name":"Placebo to upadacitinib","otherNames":[]}],"arms":[{"label":"Upadacitinib 30 mg QD","type":"EXPERIMENTAL"},{"label":"Dupilumab 300 mg EOW","type":"EXPERIMENTAL"}],"summary":"This study will evaluate upadacitinib compared to dupilumab (Dupixent®) in adults with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.","primaryOutcome":{"measure":"Percentage of Participants Achieving a 75% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 75) at Week 16","timeFrame":"Baseline and Week 16","effectByArm":[{"arm":"Dupilumab 300 mg EOW","deltaMin":62.6,"sd":null},{"arm":"Upadacitinib 30 mg QD","deltaMin":72.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.007"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":6},"locations":{"siteCount":159,"countries":["United States","Australia","Canada","Croatia","Czechia","Finland","France","Germany","Hungary","Ireland","Israel","Italy","Malaysia","Netherlands","New Zealand","Norway","Poland","Singapore","Spain","Sweden","Taiwan","Ukraine","United Kingdom"]},"refs":{"pmids":["34347860","40457140","39110139"],"seeAlso":["https://www.rxabbvie.com/"]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":331},"commonTop":["ACNE","DERMATITIS ATOPIC","NASOPHARYNGITIS","UPPER RESPIRATORY TRACT INFECTION","HEADACHE"]}}